Showing results (281-290 of 2,810) with videos related to

Sort By:
Pageof 281
Expert Opinion on Drug Safety|May 21, 2019
The safety of eribulin for the treatment of metastatic breast cancerJose Manuel Perez-Garcia, Javier Cortes
Expert Opinion on Drug Safety|March 18, 2022
Ayahuasca, a potentially rapid acting antidepressant: focus on safety and tolerabilityGiordano Novak Rossi, Isabella Caroline da Silva Dias, Glen Baker, et al.
Expert Opinion on Drug Safety|March 24, 2022
Phenytoin and damage to the cerebellum - a systematic review of published casesRobin Ferner, Rachael Day, Sally M Bradberry
Expert Opinion on Drug Safety|March 7, 2022
A comparison of the safety, feasibility, and tolerability of ECT and ketamine for treatment-resistant depressionAmanda Tamman, Amit Anand, Sanjay J Mathew
Expert Opinion on Drug Safety|March 22, 2022
Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance studyKohei Kaku, Kazuhiro Yamamoto, Yumiko Fukushima, et al.
Expert Opinion on Drug Safety|September 15, 2019
Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: a pharmacovigilance-pharmacodynamic/pharmacokinetic assessment through an analysis of the vigibase®Carla Carnovale, Faizan Mazhar, Elena Arzenton, et al.
Expert Opinion on Drug Safety|September 17, 2019
Adaptation of a deprescription intervention to the medication management of older people living in long-term care facilitiesGregorio Sanz-Tamargo, Sergio García-Cases, Andrés Navarro, et al.
Expert Opinion on Drug Safety|October 4, 2019
A drug safety evaluation of apixaban for the treatment of atrial fibrillation, acute coronary syndrome, and percutaneous coronary interventionJakub Gumprecht, Magdalena Domek, Gregory Y H Lip
Expert Opinion on Drug Safety|January 18, 2021
Safety and tolerability of sacubitril-valsartan: a systematic review and meta-analysisGonçalo Martins E Pereira, Gonçalo S Duarte, Vasyl Katerenchuk, et al.
Expert Opinion on Drug Safety|February 28, 2019
Understanding the cardiovascular risk with non-insulin antidiabetic drugsVasilios G Athyros, Konstantinos Imprialos, Konstantinos Stavropoulos, et al.
Pageof 281